Background: Antibodies against aquaporin-4 (AQP4-ab) have diagnostic and prognostic value. However, little is known to date about their utility in the first event of optic neuritis (ON). Objective: To evaluate the utility of systematic AQP4-ab determination in a retrospective cohort of patients with a first onset of ON. Patients and Methods: All patients (n = 42) were tested for AQP4-ab in the following context: typical ON (TON) and atypical ON (AON). Clinical, radiological and biochemical data were collected; patients with TON vs. AON and AQP4-ab positive vs. negative were compared. Results: The proportion of AQP4-ab seropositive patients was 40% in the TON group vs. 40.9% in the AON group. Visual acuity (VA) at baseline was poor in AON patients (p = 0.02) and these patients were associated with worse VA outcome (p < 0.001) at 6 months compared with TON patients, with a median follow-up of 3.27 ± 1.79 years. Brain MRI with dissemination in space criteria (p < 0.001), spinal cord partial lesions (p < 0.001) and oligoclonal bands (p = 0.02) were associated with the initial stages of TON. VA severity, number of myelitis attacks and ON relapses did not differ significantly between seropositive and seronegative patients. AQP4-ab were detected only in neuromyelitis optica spectrum disorders patients. Conclusion: This study showed a high seropositivity for AQP4-ab in TON patients, suggesting that it could diagnostic utility at the onset of ON.

Keywords:
Neuromyelitis optica spectrum disorders, Multiple sclerosis , Optic neuritis, Aquaporin-4 antibodies, Prognosis
1.
Toosy AT, Mason DF, Miller DH: Optic neuritis. Lancet Neurol 2014;13:83-99.
2.
Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al: Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-1174.
3.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
4.
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
5.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
6.
Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al: Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
7.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
8.
Wingerchuk DM, Hogancamp WF, O'brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
9.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
10.
Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT: Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2010;81:109-111.
11.
Costa C, Arrambide G, Tintore M, Castilló J, Sastre-Garriga J, Tur C, et al: Value of NMO-IgG determination at the time of presentation as CIS. Neurology 2012;78:1608-1611.
12.
Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al: Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010;298:158-162.
13.
Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al: Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.
14.
Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC: Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 2008;126:12-16.
15.
Burman J, Raininko R, Fagius J: Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurol Scand 2011;123:207-210.
16.
Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al: NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-2200.
17.
Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al: Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.
18.
Optic Neuritis Study Group: Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 2008;115:1079-1082.e5.
19.
Beck RW, Cleary PA, Backlund JC: The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology 1994;101:1771-1778.
20.
Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N: Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007;69:508-514.
21.
Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al: Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306:82-90.
22.
Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al: Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015;72:81-87.
23.
Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al: IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010;75:1423-1427.
24.
Palace J, Leite MI, Nairne A, Vincent A: Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67:1016-1017.
25.
Min JH, Kim BJ, Lee KH: Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-115.
26.
Juryńczyk M, Zaleski K, Selmaj K: Natalizumab and the development of extensive brain lesions in neuromyelitis optica. J Neurol 2013;260:1919-1921.
27.
Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, et al: Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012;79:1065-1066.
28.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al: Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-245.
29.
Patrucco L, Rojas JI, Miguez JS, Cristiano E: Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes. Mult Scler 2013;19:1297-1301.
30.
Juryńczyk M, Craner M, Palace J: Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 2015;86:20-25.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.